{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T04:12:23Z","timestamp":1743480743109,"version":"3.40.3"},"reference-count":152,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T00:00:00Z","timestamp":1732924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T00:00:00Z","timestamp":1732924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["5\/13\/55\/2020\/NCD-III"],"award-info":[{"award-number":["5\/13\/55\/2020\/NCD-III"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board","doi-asserted-by":"crossref","award":["TAR\/2018\/001054"],"award-info":[{"award-number":["TAR\/2018\/001054"]}],"id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Biol Eng Comput"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s11517-024-03233-6","type":"journal-article","created":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T01:32:09Z","timestamp":1732930329000},"page":"933-957","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Artificial blood\u2014hope and the challenges to combat tumor hypoxia for anti-cancer therapy"],"prefix":"10.1007","volume":"63","author":[{"given":"Rishabh","family":"Sharma","sequence":"first","affiliation":[]},{"given":"Manju","family":"Kashyap","sequence":"additional","affiliation":[]},{"given":"Hatem","family":"Zayed","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7072-0845","authenticated-orcid":false,"given":"Lucky","family":"Krishnia","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3064-8452","authenticated-orcid":false,"given":"Manoj Kumar","family":"Kashyap","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2024,11,30]]},"reference":[{"issue":"2","key":"3233_CR1","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1080\/08998280.2001.11927754","volume":"14","author":"L Kresie","year":"2001","unstructured":"Kresie L (2001) Artificial blood: an update on current red cell and platelet substitutes. Proc (Baylor Univ Med Cent) 14(2):158","journal-title":"Proc (Baylor Univ Med Cent)"},{"issue":"3","key":"3233_CR2","doi-asserted-by":"publisher","first-page":"140","DOI":"10.4103\/0972-5229.43685","volume":"12","author":"S Sarkar","year":"2008","unstructured":"Sarkar S (2008) Artificial blood. Indian J Crit Care Med 12(3):140\u2013144","journal-title":"Indian J Crit Care Med"},{"key":"3233_CR3","first-page":"481","volume":"12","author":"M Paul","year":"2021","unstructured":"Paul M (2021) A review on artificial blood. J Blood Disord Transfus 12:481","journal-title":"J Blood Disord Transfus"},{"issue":"1","key":"3233_CR4","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.15190\/d.2020.1","volume":"8","author":"F Khan","year":"2020","unstructured":"Khan F, Singh K, Friedman MT (2020) Artificial blood: the history and current perspectives of blood substitutes. Discoveries 8(1):e104","journal-title":"Discoveries"},{"key":"3233_CR5","doi-asserted-by":"crossref","unstructured":"Krishnia L, Kashyap MK (2024) Development of compendium for esophageal squamous cell carcinoma. J Vis Exp (206):e65480","DOI":"10.3791\/65480"},{"key":"3233_CR6","unstructured":"Sharma R, Sharma S (2023) Physiology, Blood Volume.\u00a0In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-.\u00a0Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK526077\/"},{"key":"3233_CR7","unstructured":"Dean L (2005)\u00a0Blood groups and red cell antigens: NCBI"},{"issue":"1","key":"3233_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2174\/1871525717666190617120045","volume":"17","author":"R Haldar","year":"2019","unstructured":"Haldar R, Gupta D, Chitranshi S, Singh MK, Sachan S (2019) Artificial blood: a futuristic dimension of modern day transfusion sciences. Cardiovasc Hematol Agents Med Chem 17(1):11\u201316","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"key":"3233_CR9","doi-asserted-by":"publisher","first-page":"36782","DOI":"10.1038\/srep36782","volume":"6","author":"K Yamada","year":"2016","unstructured":"Yamada K, Yokomaku K, Kureishi M, Akiyama M, Kihira K, Komatsu T (2016) Artificial blood for dogs. Sci Rep 6:36782","journal-title":"Artificial blood for dogs Scientific reports"},{"issue":"1","key":"3233_CR10","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.beha.2016.08.007","volume":"29","author":"MY Choi","year":"2016","unstructured":"Choi MY, Kashyap MK, Kumar D (2016) The chronic lymphocytic leukemia microenvironment: beyond the B-cell receptor. Best Pract Res Clin Haematol 29(1):40\u201353","journal-title":"Best Pract Res Clin Haematol"},{"issue":"1","key":"3233_CR11","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s13045-017-0435-x","volume":"10","author":"MK Kashyap","year":"2017","unstructured":"Kashyap MK, Amaya-Chanaga CI, Kumar D, Simmons B, Huser N, Gu Y et al (2017) Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia. J Hematol Oncol 10(1):112","journal-title":"J Hematol Oncol"},{"key":"3233_CR12","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3389\/fcell.2019.00004","volume":"7","author":"W Al Tameemi","year":"2019","unstructured":"Al Tameemi W, Dale TP, Al-Jumaily RMK, Forsyth NR (2019) Hypoxia-modified cancer cell metabolism. Front Cell Dev Biol 7:4","journal-title":"Frontiers in cell and developmental biology"},{"key":"3233_CR13","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.canlet.2020.12.020","volume":"502","author":"F Paredes","year":"2021","unstructured":"Paredes F, Williams HC, San MA (2021) Metabolic adaptation in hypoxia and cancer. Cancer Lett 502:133\u2013142","journal-title":"Cancer Lett"},{"issue":"2","key":"3233_CR14","first-page":"51","volume":"80","author":"JE Ziello","year":"2007","unstructured":"Ziello JE, Jovin IS, Huang Y (2007) Hypoxia-inducible factor (HIF)-1 regulatory pathway and its potential for therapeutic intervention in malignancy and ischemia. Yale J Biol Med 80(2):51\u201360","journal-title":"Yale J Biol Med"},{"issue":"1","key":"3233_CR15","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","volume":"8","author":"ZL Liu","year":"2023","unstructured":"Liu ZL, Chen HH, Zheng LL, Sun LP, Shi L (2023) Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Signal Transduct Target Ther 8(1):198","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"3233_CR16","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41392-023-01332-8","volume":"8","author":"Z Chen","year":"2023","unstructured":"Chen Z, Han F, Du Y, Shi H, Zhou W (2023) Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. Signal Transduct Target Ther 8(1):70","journal-title":"Signal Transduct Target Ther"},{"key":"3233_CR17","doi-asserted-by":"publisher","first-page":"153303382110363","DOI":"10.1177\/15330338211036304","volume":"20","author":"Y Li","year":"2021","unstructured":"Li Y, Zhao L, Li XF (2021) Hypoxia and the tumor microenvironment. Technol Cancer Res Treat 20:15330338211036304","journal-title":"Technol Cancer Res Treat"},{"issue":"1","key":"3233_CR18","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12935-020-01719-5","volume":"21","author":"A Emami Nejad","year":"2021","unstructured":"Emami Nejad A, Najafgholian S, Rostami A, Sistani A, Shojaeifar S, Esparvarinha M et al (2021) The role of hypoxia in the tumor microenvironment and development of cancer stem cell: a novel approach to developing treatment. Cancer Cell Int 21(1):62","journal-title":"Cancer Cell Int"},{"issue":"19","key":"3233_CR19","doi-asserted-by":"publisher","first-page":"2808","DOI":"10.2174\/1381612822666160217130049","volume":"22","author":"H Alimoradi","year":"2016","unstructured":"Alimoradi H, Matikonda SS, Gamble AB, Giles GI, Greish K (2016) Hypoxia responsive drug delivery systems in tumor therapy. Curr Pharm Des 22(19):2808\u20132820","journal-title":"Curr Pharm Des"},{"issue":"3","key":"3233_CR20","doi-asserted-by":"publisher","first-page":"678","DOI":"10.3390\/cells10030678","volume":"10","author":"R Shi","year":"2021","unstructured":"Shi R, Liao C, Zhang Q (2021) Hypoxia-driven effects in cancer: characterization, mechanisms, and therapeutic implications. Cells 10(3):678","journal-title":"Cells"},{"issue":"Suppl 5","key":"3233_CR21","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1634\/theoncologist.9-90005-4","volume":"9","author":"P Vaupel","year":"2004","unstructured":"Vaupel P, Harrison L (2004) Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. Oncologist 9(Suppl 5):4\u20139","journal-title":"Oncologist"},{"issue":"1","key":"3233_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40675-017-0062-7","volume":"3","author":"JC Jun","year":"2017","unstructured":"Jun JC, Rathore A, Younas H, Gilkes D, Polotsky VY (2017) Hypoxia-inducible factors and cancer. Curr Sleep Med Rep 3(1):1\u201310","journal-title":"Current sleep medicine reports"},{"issue":"2","key":"3233_CR23","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/BF00689633","volume":"13","author":"BA Teicher","year":"1994","unstructured":"Teicher BA (1994) Hypoxia and drug resistance. Cancer Metastasis Rev 13(2):139\u2013168","journal-title":"Cancer Metastasis Rev"},{"issue":"35","key":"3233_CR24","doi-asserted-by":"publisher","first-page":"1701429","DOI":"10.1002\/adma.201701429","volume":"29","author":"M Gao","year":"2017","unstructured":"Gao M, Liang C, Song X, Chen Q, Jin Q, Wang C et al (2017) Erythrocyte-membrane-enveloped perfluorocarbon as nanoscale artificial red blood cells to relieve tumor hypoxia and enhance cancer radiotherapy. Adv Mater 29(35):1701429","journal-title":"Adv Mater"},{"issue":"4","key":"3233_CR25","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.tibtech.2014.02.006","volume":"32","author":"AI Alayash","year":"2014","unstructured":"Alayash AI (2014) Blood substitutes: why haven\u2019t we been more successful? Trends Biotechnol 32(4):177\u2013185","journal-title":"Trends Biotechnol"},{"issue":"4","key":"3233_CR26","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1080\/10731190903043218","volume":"37","author":"W Wu","year":"2009","unstructured":"Wu W, Yang Q, Wu W, Yang Q, Li T, Zhang P et al (2009) Hemoglobin-based oxygen carriers combined with anticancer drugs may enhance sensitivity of radiotherapy and chemotherapy to solid tumors. Artif Cells Blood Substitut Biotechnol 37(4):163\u2013165","journal-title":"Artificial cells, blood substitutes, and biotechnology"},{"issue":"4","key":"3233_CR27","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1080\/10731190500289750","volume":"33","author":"A Gottschalk","year":"2005","unstructured":"Gottschalk A, Raabe A, Hommel M, Rempf C, Freitag M, Standl T (2005) Influence of the hemoglobin solution HBOC-201 on tissue oxygenation in the rat R1H-tumor. Artif Cells Blood Substit Immobil Biotechnol 33(4):379\u2013389","journal-title":"Artif Cells Blood Substit Immobil Biotechnol"},{"issue":"49","key":"3233_CR28","doi-asserted-by":"publisher","first-page":"85311","DOI":"10.18632\/oncotarget.19672","volume":"8","author":"X Qi","year":"2017","unstructured":"Qi X, Wong BL, Lau SH, Ng KT, Kwok SY, Kin-Wai Sun C et al (2017) A hemoglobin-based oxygen carrier sensitized Cisplatin based chemotherapy in hepatocellular carcinoma. Oncotarget 8(49):85311\u201385325","journal-title":"Oncotarget"},{"issue":"2","key":"3233_CR29","doi-asserted-by":"publisher","first-page":"656","DOI":"10.21037\/tcr-20-2768","volume":"10","author":"E Chow","year":"2021","unstructured":"Chow E, Lau JSH, Wai T, Lam IPY (2021) The anti-tumoral effects of the oxygen carrier YQ23 in a triple-negative breast cancer syngeneic model. Transl Cancer Res 10(2):656\u2013668","journal-title":"Translational cancer research"},{"issue":"42","key":"3233_CR30","doi-asserted-by":"publisher","first-page":"3770","DOI":"10.18632\/oncotarget.27776","volume":"11","author":"A Lucas","year":"2020","unstructured":"Lucas A, Belcher DA, Munoz C, Williams AT, Palmer AF, Cabrales P (2020) Polymerized human hemoglobin increases the effectiveness of cisplatin-based chemotherapy in non-small cell lung cancer. Oncotarget 11(42):3770\u20133781","journal-title":"Oncotarget"},{"issue":"1","key":"3233_CR31","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1080\/21691401.2023.2176865","volume":"51","author":"B Li","year":"2023","unstructured":"Li B, Zhang J, Ma N, Li W, You G, Chen G et al (2023) PEG-conjugated bovine haemoglobin enhances efficiency of chemotherapeutic agent doxorubicin with alleviating DOX-induced splenocardiac toxicity in the breast cancer. Artif Cells Nanomed Biotechnol 51(1):120\u2013130","journal-title":"Artificial cells, nanomedicine, and biotechnology"},{"issue":"6","key":"3233_CR32","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1080\/10731190802554109","volume":"36","author":"M Dai","year":"2008","unstructured":"Dai M, Yu M, Han J, Li H, Cui P, Liu Q et al (2008) PEG-conjugated hemoglobin combination with cisplatin enforced the antiangiogeic effect in a cervical tumor xenograft model. Artif Cells Blood Substit Immobil Biotechnol 36(6):487\u2013497","journal-title":"Artif Cells Blood Substit Immobil Biotechnol"},{"issue":"5","key":"3233_CR33","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1080\/10731190802369789","volume":"36","author":"J Han","year":"2008","unstructured":"Han J, Yu M, Dai M, Cui P, Li H, Zhang J et al (2008) Effect of artificial oxygen carrier with chemotherapy on tumor hypoxia and neovascularization. Artif Cells Blood Substit Immobil Biotechnol 36(5):431\u2013438","journal-title":"Artif Cells Blood Substit Immobil Biotechnol"},{"issue":"3643","key":"3233_CR34","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1126\/science.146.3643.524","volume":"146","author":"TM Chang","year":"1964","unstructured":"Chang TM (1964) Semipermeable Microcapsules. Science 146(3643):524\u2013525","journal-title":"Science"},{"key":"3233_CR35","unstructured":"Chang TMS. Artificial cells: Charles C. Thomas Publisher; 1972."},{"issue":"6","key":"3233_CR36","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/S0006-291X(71)80260-7","volume":"44","author":"TM Chang","year":"1971","unstructured":"Chang TM (1971) Stabilisation of enzymes by microencapsulation with a concentrated protein solution or by microencapsulation followed by cross-linking with glutaraldehyde. Biochem Biophys Res Commun 44(6):1531\u20131536","journal-title":"Biochem Biophys Res Commun"},{"key":"3233_CR37","doi-asserted-by":"publisher","DOI":"10.1142\/6395","volume-title":"Monograph on artificial cells: Biotechnology, Nanotechnology","author":"TMS Chang","year":"2007","unstructured":"Chang TMS (2007) Monograph on artificial cells: biotechnology, nanotechnology. Regenerative Medicine, Bioencapsulation, Cell\/Stem Cell Therapy World Science Publisher, Blood Substitutes"},{"key":"3233_CR38","unstructured":"Chang TMS. Blood substitutes: principles, methods, products and clinical trials: Vol. 2: S.Karger AG; 1998."},{"key":"3233_CR39","doi-asserted-by":"crossref","unstructured":"Gould SA, Moore EE, Hoyt DB, Ness PM, Norris EJ, Carson JL, et al. The life-sustaining capacity of human polymerized hemoglobin when red cells might be unavailable. Journal of the American College of Surgeons. 2002;195(4):445\u201352; discussion 52\u20135.","DOI":"10.1016\/S1072-7515(02)01335-2"},{"key":"3233_CR40","doi-asserted-by":"crossref","unstructured":"Pearce LB, Gawryl MS, Rentko VT, Moon-Massat PF, Rausch CW. HBOC-201 (hemoglobin glutamer-250)(bovine), hemopure\u00ae): clinical studies. Blood substitutes. 2006:437\u201350.","DOI":"10.1016\/B978-012759760-7\/50047-0"},{"issue":"11","key":"3233_CR41","doi-asserted-by":"publisher","first-page":"4530","DOI":"10.1021\/acs.molpharmaceut.9b00663","volume":"16","author":"MS Jiang","year":"2019","unstructured":"Jiang MS, Yin XY, Qin B, Xuan SY, Yuan XL, Yin H et al (2019) Inhibiting hypoxia and chemotherapy-induced cancer cell metastasis under a valid therapeutic effect by an assistance of biomimetic oxygen delivery. Mol Pharm 16(11):4530\u20134541","journal-title":"Mol Pharm"},{"issue":"4","key":"3233_CR42","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.apsb.2019.01.011","volume":"9","author":"Q Xia","year":"2019","unstructured":"Xia Q, Zhang Y, Li Z, Hou X, Feng N (2019) Red blood cell membrane-camouflaged nanoparticles: a novel drug delivery system for antitumor application. Acta pharmaceutica Sinica B 9(4):675\u2013689","journal-title":"Acta pharmaceutica Sinica B"},{"issue":"2","key":"3233_CR43","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/j.1525-1594.2011.01418.x","volume":"36","author":"C Murayama","year":"2012","unstructured":"Murayama C, Kawaguchi AT, Ishikawa K, Kamijo A, Kato N, Ohizumi Y et al (2012) Liposome-encapsulated hemoglobin ameliorates tumor hypoxia and enhances radiation therapy to suppress tumor growth in mice. Artif Organs 36(2):170\u2013177","journal-title":"Artif Organs"},{"key":"3233_CR44","first-page":"814s","volume":"50","author":"RK Jain","year":"1990","unstructured":"Jain RK (1990) Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 50:814s\u20139s","journal-title":"Cancer research."},{"issue":"1","key":"3233_CR45","doi-asserted-by":"publisher","first-page":"e112","DOI":"10.1002\/cpps.112","volume":"101","author":"C Natarajan","year":"2020","unstructured":"Natarajan C, Signore AV, Kumar V, Storz JF (2020) Synthesis of recombinant human hemoglobin with NH(2) -terminal acetylation in Escherichia coli. Curr Protoc Protein Sci 101(1):e112","journal-title":"Curr Protoc Protein Sci"},{"issue":"5","key":"3233_CR46","doi-asserted-by":"publisher","first-page":"e20176","DOI":"10.1371\/journal.pone.0020176","volume":"6","author":"C Natarajan","year":"2011","unstructured":"Natarajan C, Jiang X, Fago A, Weber RE, Moriyama H, Storz JF (2011) Expression and purification of recombinant hemoglobin in Escherichia coli. PLoS ONE 6(5):e20176","journal-title":"PLoS ONE"},{"issue":"2","key":"3233_CR47","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s00424-020-02482-2","volume":"473","author":"J Jagers","year":"2021","unstructured":"Jagers J, Wrobeln A, Ferenz KB (2021) Perfluorocarbon-based oxygen carriers: from physics to physiology. Pflugers Arch 473(2):139\u2013150","journal-title":"Pflugers Arch"},{"key":"3233_CR48","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.coph.2020.08.010","volume":"53","author":"MP Krafft","year":"2020","unstructured":"Krafft MP (2020) Alleviating tumor hypoxia with perfluorocarbon-based oxygen carriers. Curr Opin Pharmacol 53:117\u2013125","journal-title":"Curr Opin Pharmacol"},{"issue":"9","key":"3233_CR49","doi-asserted-by":"publisher","first-page":"e0184250","DOI":"10.1371\/journal.pone.0184250","volume":"12","author":"LA Feldman","year":"2017","unstructured":"Feldman LA, Fabre MS, Grasso C, Reid D, Broaddus WC, Lanza GM et al (2017) Perfluorocarbon emulsions radiosensitise brain tumors in carbogen breathing mice with orthotopic GL261 gliomas. PLoS ONE 12(9):e0184250","journal-title":"PLoS ONE"},{"issue":"8","key":"3233_CR50","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1016\/j.ultrasmedbio.2021.04.003","volume":"47","author":"R Guo","year":"2021","unstructured":"Guo R, Xu N, Liu Y, Ling G, Yu J, Zhang P (2021) Functional ultrasound-triggered phase-shift perfluorocarbon nanodroplets for cancer therapy. Ultrasound Med Biol 47(8):2064\u20132079","journal-title":"Ultrasound Med Biol"},{"issue":"3","key":"3233_CR51","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1054\/blre.1999.0113","volume":"13","author":"KC Lowe","year":"1999","unstructured":"Lowe KC (1999) Perfluorinated blood substitutes and artificial oxygen carriers. Blood Rev 13(3):171\u2013184","journal-title":"Blood Rev"},{"issue":"7","key":"3233_CR52","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1111\/j.1537-2995.2010.02603.x","volume":"50","author":"LL Donahue","year":"2010","unstructured":"Donahue LL, Shapira I, Shander A, Kolitz J, Allen S, Greenburg G (2010) Management of acute anemia in a Jehovah\u2019s Witness patient with acute lymphoblastic leukemia with polymerized bovine hemoglobin-based oxygen carrier: a case report and review of literature. Transfusion 50(7):1561\u20131567","journal-title":"Transfusion"},{"issue":"6","key":"3233_CR53","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1158\/1055-9965.EPI-19-1623","volume":"29","author":"R Peila","year":"2020","unstructured":"Peila R, Rohan TE (2020) Diabetes, glycated hemoglobin, and risk of cancer in the UK Biobank Study. Cancer Epidemiol Biomarkers Prev 29(6):1107\u20131119","journal-title":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology"},{"issue":"6","key":"3233_CR54","doi-asserted-by":"publisher","first-page":"473","DOI":"10.2217\/bmm-2021-0577","volume":"16","author":"G Chi","year":"2022","unstructured":"Chi G, Lee JJ, Montazerin SM, Marszalek J (2022) Prognostic value of hemoglobin-to-red cell distribution width ratio in cancer: a systematic review and meta-analysis. Biomark Med 16(6):473\u2013482","journal-title":"Biomark Med"},{"issue":"6","key":"3233_CR55","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/mc.23404","volume":"61","author":"N Kang","year":"2022","unstructured":"Kang N, Qiu WJ, Wang B, Tang DF, Shen XY (2022) Role of hemoglobin alpha and hemoglobin beta in non-small-cell lung cancer based on bioinformatics analysis. Mol Carcinog 61(6):587\u2013602","journal-title":"Mol Carcinog"},{"key":"3233_CR56","doi-asserted-by":"publisher","first-page":"100836","DOI":"10.1016\/j.mex.2020.100836","volume":"7","author":"S Blair","year":"2020","unstructured":"Blair S, Barlow C, Martin E, Schumaker R, McIntyre J (2020) Methemoglobin determination by multi-component analysis in coho salmon (Oncorhynchus kisutch) possessing unstable hemoglobin. MethodsX 7:100836","journal-title":"MethodsX"},{"issue":"6","key":"3233_CR57","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.3390\/antiox12061198","volume":"12","author":"A Carrola","year":"2023","unstructured":"Carrola A, Romao CC, Vieira HLA (2023) Carboxyhemoglobin (COHb): unavoidable bystander or protective player? Antioxidants 12(6):1198","journal-title":"Antioxidants"},{"issue":"17","key":"3233_CR58","doi-asserted-by":"publisher","first-page":"13557","DOI":"10.3390\/ijms241713557","volume":"24","author":"ID Kuleshova","year":"2023","unstructured":"Kuleshova ID, Zaripov PI, Poluektov YM, Anashkina AA, Kaluzhny DN, Parshina EY et al (2023) Changes in Hemoglobin properties in complex with glutathione and after glutathionylation. Int J Mol Sci 24(17):13557","journal-title":"Int J Mol Sci"},{"issue":"4","key":"3233_CR59","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1053\/j.jvca.2013.02.005","volume":"28","author":"JA Cortazzo","year":"2014","unstructured":"Cortazzo JA, Lichtman AD (2014) Methemoglobinemia: a review and recommendations for management. J Cardiothorac Vasc Anesth 28(4):1043\u20131047","journal-title":"J Cardiothorac Vasc Anesth"},{"issue":"11","key":"3233_CR60","doi-asserted-by":"publisher","first-page":"660","DOI":"10.3390\/toxins11110660","volume":"11","author":"M Frimat","year":"2019","unstructured":"Frimat M, Boudhabhay I, Roumenina LT (2019) Hemolysis derived products toxicity and endothelium: model of the second hit. Toxins 11(11):660","journal-title":"Toxins"},{"key":"3233_CR61","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2147\/HP.S93413","volume":"3","author":"B Muz","year":"2015","unstructured":"Muz B, de la Puente P, Azab F, Azab AK (2015) The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia 3:83\u201392","journal-title":"Hypoxia"},{"issue":"8","key":"3233_CR62","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.tips.2017.05.002","volume":"38","author":"GZ Qiu","year":"2017","unstructured":"Qiu GZ, Jin MZ, Dai JX, Sun W, Feng JH, Jin WL (2017) Reprogramming of the tumor in the hypoxic niche: the emerging concept and associated therapeutic strategies. Trends Pharmacol Sci 38(8):669\u2013686","journal-title":"Trends Pharmacol Sci"},{"issue":"6","key":"3233_CR63","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/nrc3064","volume":"11","author":"WR Wilson","year":"2011","unstructured":"Wilson WR, Hay MP (2011) Targeting hypoxia in cancer therapy. Nat Rev Cancer 11(6):393\u2013410","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"3233_CR64","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1021\/acs.jctc.4c00029","volume":"20","author":"M Jiang","year":"2024","unstructured":"Jiang M, Yu CH, Xu Z, Qin Z (2024) Binding of carbon monoxide to hemoglobin in an oxygen environment: force field development for molecular dynamics. J Chem Theory Comput 20(10):4229\u20134238","journal-title":"J Chem Theory Comput"},{"issue":"23","key":"3233_CR65","doi-asserted-by":"publisher","first-page":"7009","DOI":"10.1158\/0008-5472.CAN-13-1075","volume":"73","author":"B Wegiel","year":"2013","unstructured":"Wegiel B, Gallo D, Csizmadia E, Harris C, Belcher J, Vercellotti GM et al (2013) Carbon monoxide expedites metabolic exhaustion to inhibit tumor growth. Cancer Res 73(23):7009\u20137021","journal-title":"Cancer Res"},{"issue":"10","key":"3233_CR66","doi-asserted-by":"publisher","first-page":"3945","DOI":"10.1111\/cas.15068","volume":"112","author":"H Nakamura","year":"2021","unstructured":"Nakamura H, Takada K (2021) Reactive oxygen species in cancer: current findings and future directions. Cancer Sci 112(10):3945\u20133952","journal-title":"Cancer Sci"},{"key":"3233_CR67","doi-asserted-by":"publisher","first-page":"658315","DOI":"10.3389\/fimmu.2021.658315","volume":"12","author":"KN Luu Hoang","year":"2021","unstructured":"Luu Hoang KN, Anstee JE, Arnold JN (2021) The diverse roles of heme oxygenase-1 in tumor progression. Front Immunol 12:658315","journal-title":"Front Immunol"},{"issue":"3","key":"3233_CR68","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.cell.2012.01.021","volume":"148","author":"GL Semenza","year":"2012","unstructured":"Semenza GL (2012) Hypoxia-inducible factors in physiology and medicine. Cell 148(3):399\u2013408","journal-title":"Cell"},{"issue":"1","key":"3233_CR69","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nrc704","volume":"2","author":"AL Harris","year":"2002","unstructured":"Harris AL (2002) Hypoxia\u2013a key regulatory factor in tumour growth. Nat Rev Cancer 2(1):38\u201347","journal-title":"Nat Rev Cancer"},{"key":"3233_CR70","doi-asserted-by":"publisher","first-page":"1974233","DOI":"10.1080\/2162402X.2021.1974233","volume":"10","author":"G Hassan Venkatesh","year":"2021","unstructured":"Hassan Venkatesh G, Abou Khouzam R, Shaaban Moustafa Elsayed W, Ahmed Zeinelabdin N, Terry S, Chouaib S (2021) Tumor hypoxia: an important regulator of tumor progression or a potential modulator of tumor immunogenicity? Oncoimmunology. 10:1974233","journal-title":"Oncoimmunology."},{"issue":"4","key":"3233_CR71","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/0360-3016(91)90737-O","volume":"21","author":"BA Teicher","year":"1991","unstructured":"Teicher BA, Herman TS, Hopkins RE, Menon K (1991) Effect of oxygen level on the enhancement of tumor response to radiation by perfluorochemical emulsions or a bovine hemoglobin preparation. Int J Radiat Oncol Biol Phys 21(4):969\u2013974","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2\u20134","key":"3233_CR72","doi-asserted-by":"publisher","first-page":"899","DOI":"10.3109\/10731199209119737","volume":"20","author":"BA Teicher","year":"1992","unstructured":"Teicher BA, Herman TS, Menon K (1992) Enhancement of fractionated radiation therapy by an experimental concentrated perflubron emulsion (Oxygent) in the Lewis lung carcinoma. Biomater Artif Cells Immobilization Biotechnol 20(2\u20134):899\u2013902","journal-title":"Biomaterials, artificial cells, and immobilization biotechnology: official journal of the International Society for Artificial Cells and Immobilization Biotechnology"},{"issue":"3","key":"3233_CR73","doi-asserted-by":"publisher","first-page":"827","DOI":"10.3109\/10731199409117917","volume":"22","author":"BA Teicher","year":"1994","unstructured":"Teicher BA, Holden SA, Dupuis NP, Kusomoto T, Liu M, Liu F et al (1994) Oxygenation of the rat 9L gliosarcoma and the rat 13672 mammary carcinoma with various doses of a hemoglobin solution. Artif Cells Blood Substit Immobil Biotechnol 22(3):827\u2013833","journal-title":"Artif Cells Blood Substit Immobil Biotechnol"},{"issue":"2","key":"3233_CR74","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/(SICI)1096-9098(199606)62:2<109::AID-JSO6>3.0.CO;2-C","volume":"62","author":"M Nozue","year":"1996","unstructured":"Nozue M, Lee I, Manning JM, Manning LR, Jain RK (1996) Oxygenation in tumors by modified hemoglobins. J Surg Oncol 62(2):109\u2013114","journal-title":"J Surg Oncol"},{"issue":"11","key":"3233_CR75","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1007\/s00066-005-1418-3","volume":"181","author":"A Raabe","year":"2005","unstructured":"Raabe A, Gottschalk A, Hommel M, Dubben HH, Strandl T (2005) No effect of the hemoglobin solution HBOC-201 on the response of the rat R1H tumor to fractionated irradiation. Strahlentherapie und Onkologie\u202f: Organ der Deutschen Rontgengesellschaft [et al] 181(11):730\u2013737","journal-title":"Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft [et al]"},{"issue":"6","key":"3233_CR76","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1080\/10731190802556674","volume":"36","author":"M Yu","year":"2008","unstructured":"Yu M, Han J, Dai M, Cui P, Li H, Liu Q et al (2008) Influence of PEG-conjugated hemoglobin on tumor oxygenation and response to chemotherapy. Artif Cells Blood Substit Immobil Biotechnol 36(6):551\u2013561","journal-title":"Artif Cells Blood Substit Immobil Biotechnol"},{"issue":"1","key":"3233_CR77","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jss.2007.12.770","volume":"151","author":"M Yamamoto","year":"2009","unstructured":"Yamamoto M, Izumi Y, Horinouchi H, Teramura Y, Sakai H, Kohno M et al (2009) Systemic administration of hemoglobin vesicle elevates tumor tissue oxygen tension and modifies tumor response to irradiation. J Surg Res 151(1):48\u201354","journal-title":"J Surg Res"},{"issue":"4","key":"3233_CR78","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3109\/10731199.2012.663385","volume":"40","author":"J Han","year":"2012","unstructured":"Han J, Yu M, Dai M, Li H, Xiu R, Liu Q (2012) Decreased expression of MDR1 in PEG-conjugated hemoglobin solution combined cisplatin treatment in a tumor xenograft model. Artif Cells Blood Substit Immobil Biotechnol 40(4):239\u2013244","journal-title":"Artif Cells Blood Substit Immobil Biotechnol"},{"issue":"4","key":"3233_CR79","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3109\/21691401.2013.808647","volume":"42","author":"XB Liu","year":"2014","unstructured":"Liu XB, Cheng Q, Geng W, Ling CC, Liu Y, Ng KT et al (2014) Enhancement of cisplatin-based TACE by a hemoglobin-based oxygen carrier in an orthotopic rat HCC model. Artif Cells Nanomed Biotechnol 42(4):229\u2013236","journal-title":"Artificial cells, nanomedicine, and biotechnology"},{"key":"3233_CR80","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1186\/1471-2407-14-293","volume":"14","author":"CX Li","year":"2014","unstructured":"Li CX, Wong BL, Ling CC, Ma YY, Shao Y, Geng W et al (2014) A novel oxygen carrier \u201cYQ23\u201d suppresses the liver tumor metastasis by decreasing circulating endothelial progenitor cells and regulatory T cells. BMC Cancer 14:293","journal-title":"BMC Cancer"},{"issue":"6","key":"3233_CR81","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1007\/s00280-015-2897-2","volume":"76","author":"NP Lee","year":"2015","unstructured":"Lee NP, Chan KT, Choi MY, Lam HY, Tung LN, Tzang FC et al (2015) Oxygen carrier YQ23 can enhance the chemotherapeutic drug responses of chemoresistant esophageal tumor xenografts. Cancer Chemother Pharmacol 76(6):1199\u20131207","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"3233_CR82","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/aor.12825","volume":"41","author":"F Kawaguchi","year":"2017","unstructured":"Kawaguchi F, Kawaguchi AT, Murayama C, Kamijo A, Haida M (2017) Liposome-encapsulated hemoglobin improves tumor oxygenation as detected by near-infrared spectroscopy in colon carcinoma in Mice. Artif Organs 41(4):327\u2013335","journal-title":"Artif Organs"},{"issue":"2","key":"3233_CR83","doi-asserted-by":"publisher","first-page":"e0191275","DOI":"10.1371\/journal.pone.0191275","volume":"13","author":"DA Belcher","year":"2018","unstructured":"Belcher DA, Ju JA, Baek JH, Yalamanoglu A, Buehler PW, Gilkes DM et al (2018) The quaternary state of polymerized human hemoglobin regulates oxygenation of breast cancer solid tumors: a theoretical and experimental study. PLoS ONE 13(2):e0191275","journal-title":"PLoS ONE"},{"issue":"1","key":"3233_CR84","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1080\/10717544.2019.1639846","volume":"26","author":"Y Zhao","year":"2019","unstructured":"Zhao Y, Chen G, Meng Z, Gong G, Zhao W, Wang K et al (2019) A novel nanoparticle drug delivery system based on PEGylated hemoglobin for cancer therapy. Drug Delivery 26(1):717\u2013723","journal-title":"Drug Delivery"},{"issue":"10","key":"3233_CR85","first-page":"2693","volume":"49","author":"BA Teicher","year":"1989","unstructured":"Teicher BA, Herman TS, Jones SM (1989) Optimization of perfluorochemical levels with radiation therapy in mice. Cancer Res 49(10):2693\u20132697","journal-title":"Cancer Res"},{"issue":"19","key":"3233_CR86","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1042\/BCJ20160243","volume":"473","author":"GG Silkstone","year":"2016","unstructured":"Silkstone GG, Silkstone RS, Wilson MT, Simons M, Bulow L, Kallberg K et al (2016) Engineering tyrosine electron transfer pathways decreases oxidative toxicity in hemoglobin: implications for blood substitute design. Biochem J 473(19):3371\u20133383","journal-title":"Biochem J"},{"key":"3233_CR87","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/j.1749-6632.2000.tb06182.x","volume":"899","author":"JM Gutteridge","year":"2000","unstructured":"Gutteridge JM, Halliwell B (2000) Free radicals and antioxidants in the year 2000. A historical look to the future. Ann N Y Acad Sci 899:136\u201347","journal-title":"Ann N Y Acad Sci"},{"key":"3233_CR88","doi-asserted-by":"publisher","first-page":"1048951","DOI":"10.3389\/fmedt.2022.1048951","volume":"4","author":"H Sakai","year":"2022","unstructured":"Sakai H, Kure T, Taguchi K, Azuma H (2022) Research of storable and ready-to-use artificial red blood cells (hemoglobin vesicles) for emergency medicine and other clinical applications. Frontiers in medical technology 4:1048951","journal-title":"Frontiers in medical technology"},{"key":"3233_CR89","doi-asserted-by":"crossref","unstructured":"Sen Gupta A (2017) Bio-inspired nanomedicine strategies for artificial blood components. Wiley Interdiscip Rev Nanomed Nanobiotechnol Wiley Interdiscip Rev Nanomed Nanobiotechnol 9(6):10.1002\/wnan.1464","DOI":"10.1002\/wnan.1464"},{"issue":"3","key":"3233_CR90","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s12079-018-0492-0","volume":"13","author":"V Gupta","year":"2019","unstructured":"Gupta V, Bhavanasi S, Quadir M, Singh K, Ghosh G, Vasamreddy K et al (2019) Protein PEGylation for cancer therapy: bench to bedside. J Cell Commun Signal 13(3):319\u2013330","journal-title":"Journal of cell communication and signaling"},{"issue":"1","key":"3233_CR91","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-023-01668-1","volume":"9","author":"X Li","year":"2024","unstructured":"Li X, Peng X, Zoulikha M, Boafo GF, Magar KT, Ju Y et al (2024) Multifunctional nanoparticle-mediated combining therapy for human diseases. Signal Transduct Target Ther 9(1):1","journal-title":"Signal Transduct Target Ther"},{"key":"3233_CR92","doi-asserted-by":"crossref","unstructured":"Samuel Tillmans SW. Synthetic and recombinant hemoglobins. Basic Anesthesia Review Oxford University Press; 2024. p. 753.","DOI":"10.1093\/med\/9780197584569.003.0308"},{"issue":"1","key":"3233_CR93","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s40005-022-00590-y","volume":"53","author":"N Mohanto","year":"2023","unstructured":"Mohanto N, Park YJ, Jee JP (2023) Current perspectives of artificial oxygen carriers as red blood cell substitutes: a review of old to cutting-edge technologies using in vitro and in vivo assessments. J Pharm Investig 53(1):153\u2013190","journal-title":"J Pharm Investig"},{"issue":"4","key":"3233_CR94","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.trsl.2012.01.009","volume":"159","author":"TJ Lyons","year":"2012","unstructured":"Lyons TJ, Basu A (2012) Biomarkers in diabetes: hemoglobin A1c, vascular and tissue markers. Transl Res 159(4):303\u2013312","journal-title":"Translational research : the journal of laboratory and clinical medicine"},{"issue":"7","key":"3233_CR95","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1038\/s41416-021-01693-3","volume":"126","author":"J Zheng","year":"2022","unstructured":"Zheng J, Gao Y, Xie SH, Santoni G, Lagergren J (2022) Haemoglobin A1c and serum glucose levels and risk of gastric cancer: a systematic review and meta-analysis. Br J Cancer 126(7):1100\u20131107","journal-title":"Br J Cancer"},{"issue":"8","key":"3233_CR96","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1111\/dme.13031","volume":"33","author":"C Hope","year":"2016","unstructured":"Hope C, Robertshaw A, Cheung KL, Idris I, English E (2016) Relationship between HbA1c and cancer in people with or without diabetes: a systematic review. Diabet Med 33(8):1013\u20131025","journal-title":"Diabetic medicine : a journal of the British Diabetic Association"},{"issue":"9","key":"3233_CR97","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1038\/bjc.2014.150","volume":"110","author":"JC de Beer","year":"2014","unstructured":"de Beer JC, Liebenberg L (2014) Does cancer risk increase with HbA1c, independent of diabetes? Br J Cancer 110(9):2361\u20132368","journal-title":"Br J Cancer"},{"key":"3233_CR98","doi-asserted-by":"crossref","unstructured":"Venturini E, Iannuzzo G, D'Andrea A, Pacileo M, Tarantini L, Canale ML et al (2020) Oncology and cardiac rehabilitation: an underrated relationship. J Clin Med 9(6):1810","DOI":"10.3390\/jcm9061810"},{"issue":"1","key":"3233_CR99","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1177\/1010539517745630","volume":"30","author":"YH Byun","year":"2018","unstructured":"Byun YH, Kim SY, Mok Y, Kim Y, Jee SH (2018) Heart rate recovery and cancer risk: prospective cohort study. Asia Pac J Public Health 30(1):45\u201355","journal-title":"Asia Pac J Public Health"},{"issue":"4","key":"3233_CR100","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3390\/ph11040094","volume":"11","author":"F Busti","year":"2018","unstructured":"Busti F, Marchi G, Ugolini S, Castagna A, Girelli D (2018) Anemia and iron deficiency in cancer patients: role of iron replacement therapy. Pharmaceuticals 11(4):94","journal-title":"Pharmaceuticals"},{"issue":"19","key":"3233_CR101","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1093\/jnci\/91.19.1616","volume":"91","author":"JE Groopman","year":"1999","unstructured":"Groopman JE, Itri LM (1999) Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 91(19):1616\u20131634","journal-title":"J Natl Cancer Inst"},{"key":"3233_CR102","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.3389\/fphys.2018.01294","volume":"9","author":"C Madeddu","year":"2018","unstructured":"Madeddu C, Gramignano G, Astara G, Demontis R, Sanna E, Atzeni V et al (2018) Pathogenesis and treatment options of cancer related anemia: perspective for a targeted mechanism-based approach. Front Physiol 9:1294","journal-title":"Front Physiol"},{"issue":"1A","key":"3233_CR103","first-page":"23","volume":"22","author":"P Podkalicka","year":"2018","unstructured":"Podkalicka P, Mucha O, Jozkowicz A, Dulak J, Loboda A (2018) Heme oxygenase inhibition in cancers: possible tools and targets. Contemp Oncol 22(1A):23\u201332","journal-title":"Contemp Oncol"},{"issue":"4","key":"3233_CR104","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/cdd.2008.12","volume":"15","author":"A Weidemann","year":"2008","unstructured":"Weidemann A, Johnson RS (2008) Biology of HIF-1alpha. Cell Death Differ 15(4):621\u2013627","journal-title":"Cell Death Differ"},{"issue":"5","key":"3233_CR105","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.3390\/biomedicines11051330","volume":"11","author":"Y Kurota","year":"2023","unstructured":"Kurota Y, Takeda Y, Ichiyanagi O, Saitoh S, Ito H, Naito S et al (2023) Hemoglobin beta expression is associated with poor prognosis in clear cell renal cell carcinoma. Biomedicines 11(5):1330","journal-title":"Biomedicines"},{"issue":"7","key":"3233_CR106","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.18632\/oncotarget.1736","volume":"5","author":"E Borsi","year":"2014","unstructured":"Borsi E, Perrone G, Terragna C, Martello M, Dico AF, Solaini G et al (2014) Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma. Oncotarget 5(7):1779\u20131792","journal-title":"Oncotarget"},{"issue":"2","key":"3233_CR107","doi-asserted-by":"publisher","first-page":"115","DOI":"10.7555\/JBR.34.20200096","volume":"35","author":"JB Papizan","year":"2020","unstructured":"Papizan JB, Porter SN, Sharma A, Pruett-Miller SM (2020) Therapeutic gene editing strategies using CRISPR-Cas9 for the beta-hemoglobinopathies. J Biomed Res 35(2):115\u2013134","journal-title":"J Biomed Res"},{"issue":"3","key":"3233_CR108","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2029392","volume":"384","author":"EB Esrick","year":"2021","unstructured":"Esrick EB, Lehmann LE, Biffi A, Achebe M, Brendel C, Ciuculescu MF et al (2021) Post-transcriptional genetic silencing of BCL11A to treat sickle cell disease. N Engl J Med 384(3):205\u2013215","journal-title":"N Engl J Med"},{"key":"3233_CR109","doi-asserted-by":"publisher","first-page":"14344","DOI":"10.1038\/ncomms14344","volume":"8","author":"Y Zheng","year":"2017","unstructured":"Zheng Y, Miyamoto DT, Wittner BS, Sullivan JP, Aceto N, Jordan NV et al (2017) Expression of beta-globin by cancer cells promotes cell survival during blood-borne dissemination. Nat Commun 8:14344","journal-title":"Nat Commun"},{"issue":"1","key":"3233_CR110","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1080\/09537104.2021.1967916","volume":"33","author":"NF Luc","year":"2022","unstructured":"Luc NF, Rohner N, Girish A, Didar Singh Sekhon U, Neal MD, Sen Gupta A (2022) Bioinspired artificial platelets: past, present and future. Platelets. 33(1):35\u201347","journal-title":"Platelets."},{"issue":"2","key":"3233_CR111","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3109\/10731199309117350","volume":"21","author":"ME Rybak","year":"1993","unstructured":"Rybak ME, Renzulli LA (1993) A liposome based platelet substitute, the plateletsome, with hemostatic efficacy. Biomater Artif Cells Immobilization Biotechnol 21(2):101\u2013118","journal-title":"Biomaterials, artificial cells, and immobilization biotechnology: official journal of the International Society for Artificial Cells and Immobilization Biotechnology"},{"issue":"1","key":"3233_CR112","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1309\/CCDV-3BEP-XXKP-BKDM","volume":"115","author":"SS Graham","year":"2001","unstructured":"Graham SS, Gonchoroff NJ, Miller JL (2001) Infusible platelet membranes retain partial functionality of the platelet GPIb\/IX\/V receptor complex. Am J Clin Pathol 115(1):144\u2013147","journal-title":"Am J Clin Pathol"},{"key":"3233_CR113","first-page":"337","volume":"11","author":"S Nasiri","year":"2013","unstructured":"Nasiri S (2013) Infusible platelet membrane as a platelet substitute for transfusion: an overview. Blood Transfus 11:337\u201342","journal-title":"Blood transfusion=Trasfusione del sangue"},{"issue":"Suppl 1","key":"3233_CR114","first-page":"100S","volume":"53","author":"GM Fitzpatrick","year":"2013","unstructured":"Fitzpatrick GM, Cliff R, Tandon N (2013) Thrombosomes: a platelet-derived hemostatic agent for control of noncompressible hemorrhage. Transfusion 53(Suppl 1):100S-S106","journal-title":"Transfusion"},{"issue":"S2","key":"3233_CR115","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1111\/trf.15167","volume":"59","author":"JA Bynum","year":"2019","unstructured":"Bynum JA, Meledeo MA, Peltier GC, McIntosh CS, Taylor AS, Montgomery RK et al (2019) Evaluation of a lyophilized platelet-derived hemostatic product. Transfusion 59(S2):1490\u20131498","journal-title":"Transfusion"},{"issue":"1","key":"3233_CR116","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1182\/blood.V61.1.186.186","volume":"61","author":"G Agam","year":"1983","unstructured":"Agam G, Livne A (1983) Passive participation of fixed platelets in aggregation facilitated by covalently bound fibrinogen. Blood 61(1):186\u2013191","journal-title":"Blood"},{"issue":"2","key":"3233_CR117","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1667\/RADE-20-00016","volume":"194","author":"AD Sung","year":"2020","unstructured":"Sung AD, Yen RC, Jiao Y, Bernanke A, Lewis DA, Miller SE et al (2020) Fibrinogen-coated albumin nanospheres prevent thrombocytopenia-related bleeding. Radiat Res 194(2):162\u2013172","journal-title":"Radiat Res"},{"issue":"2","key":"3233_CR118","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.jss.2014.12.011","volume":"194","author":"C Verhoef","year":"2015","unstructured":"Verhoef C, Singla N, Moneta G, Muir W, Rijken A, Lockstadt H et al (2015) Fibrocaps for surgical hemostasis: two randomized, controlled phase II trials. J Surg Res 194(2):679\u2013687","journal-title":"J Surg Res"},{"issue":"28","key":"3233_CR119","doi-asserted-by":"publisher","first-page":"3864","DOI":"10.1002\/adma.201200607","volume":"24","author":"N Doshi","year":"2012","unstructured":"Doshi N, Orje JN, Molins B, Smith JW, Mitragotri S, Ruggeri ZM (2012) Platelet mimetic particles for targeting thrombi in flowing blood. Adv Mater 24(28):3864\u20133869","journal-title":"Adv Mater"},{"issue":"3","key":"3233_CR120","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/S0006-291X(02)00934-8","volume":"296","author":"S Takeoka","year":"2002","unstructured":"Takeoka S, Teramura Y, Okamura Y, Tsuchida E, Handa M, Ikeda Y (2002) Rolling properties of rGPIbalpha-conjugated phospholipid vesicles with different membrane flexibilities on vWf surface under flow conditions. Biochem Biophys Res Commun 296(3):765\u2013770","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"3233_CR121","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1182\/blood.V100.1.136","volume":"100","author":"T Nishiya","year":"2002","unstructured":"Nishiya T, Kainoh M, Murata M, Handa M, Ikeda Y (2002) Reconstitution of adhesive properties of human platelets in liposomes carrying both recombinant glycoproteins Ia\/IIa and Ib alpha under flow conditions: specific synergy of receptor-ligand interactions. Blood 100(1):136\u2013142","journal-title":"Blood"},{"key":"3233_CR122","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.3389\/fimmu.2019.01805","volume":"10","author":"AL Palacios-Acedo","year":"2019","unstructured":"Palacios-Acedo AL, Mege D, Crescence L, Dignat-George F, Dubois C, Panicot-Dubois L (2019) Platelets, thrombo-inflammation, and cancer: collaborating with the enemy. Front Immunol 10:1805","journal-title":"Front Immunol"},{"key":"3233_CR123","doi-asserted-by":"publisher","first-page":"5721258","DOI":"10.1155\/2020\/5721258","volume":"2020","author":"XH Zhu","year":"2020","unstructured":"Zhu XH, Du JX, Zhu D, Ren SZ, Chen K, Zhu HL (2020) Recent research on methods to improve tumor hypoxia environment. Oxid Med Cell Longev 2020:5721258","journal-title":"Oxid Med Cell Longev"},{"issue":"5557","key":"3233_CR124","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1126\/science.1068443","volume":"295","author":"JE Squires","year":"2002","unstructured":"Squires JE (2002) Artificial blood. Science 295(5557):1002\u20131005","journal-title":"Science"},{"key":"3233_CR125","doi-asserted-by":"publisher","first-page":"655393","DOI":"10.3389\/fphys.2021.655393","volume":"12","author":"P Thiagarajan","year":"2021","unstructured":"Thiagarajan P, Parker CJ, Prchal JT (2021) How do red blood cells die? Front Physiol 12:655393","journal-title":"Front Physiol"},{"issue":"2","key":"3233_CR126","first-page":"158","volume":"14","author":"L Kresie","year":"2001","unstructured":"Kresie L (2001) Artificial blood: an update on current red cell and platelet substitutes. Proceedings 14(2):158\u2013161","journal-title":"Proceedings"},{"issue":"9","key":"3233_CR127","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1093\/milmed\/152.9.473","volume":"152","author":"DH Marks","year":"1987","unstructured":"Marks DH, Brown DR, Ottinger WE, Atassi MZ (1987) Antibody response to transfusion with pyridoxalated polymerized hemoglobin solution. Mil Med 152(9):473\u2013477","journal-title":"Mil Med"},{"issue":"7","key":"3233_CR128","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1080\/13669877.2012.666759","volume":"15","author":"P Fleming","year":"2012","unstructured":"Fleming P, Townsend E, Van Hilten JA, Spence A, Ferguson E (2012) Expert relevance and the use of context-driven heuristic processes in risk perception. J Risk Res 15(7):857\u2013873","journal-title":"J Risk Res"},{"key":"3233_CR129","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1590\/S1807-59322009000800016","volume":"64","author":"J-Y Chen","year":"2009","unstructured":"Chen J-Y, Scerbo M, Kramer G (2009) A review of blood substitutes: examining the history, clinical trial results, and ethics of hemoglobin-based oxygen carriers. Clinics 64:803\u2013813","journal-title":"Clinics"},{"issue":"2","key":"3233_CR130","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1080\/10731190601188216","volume":"35","author":"P Fleming","year":"2007","unstructured":"Fleming P, Ferguson E, Townsend E, Lowe KC (2007) Perceptions in transfusion medicine: a pilot field study on risk and ethics for blood and blood substitutes. Artif Cells Blood Substit Biotechnol 35(2):149\u2013156","journal-title":"Artificial cells, blood substitutes, and biotechnology"},{"key":"3233_CR131","doi-asserted-by":"publisher","first-page":"6723","DOI":"10.21037\/aob-21-58","volume":"7","author":"EP Crowe","year":"2022","unstructured":"Crowe EP, DeSimone RA (2022) When blood transfusion is not an option owing to religious beliefs. Annals of Blood 7:6723","journal-title":"Annals of Blood"},{"key":"3233_CR132","unstructured":"https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/scientific-guidelines\/clinical-efficacy-safety-guidelines\/clinical-efficacy-safety-haematology-blood-products-including-biotech-alternatives."},{"issue":"2","key":"3233_CR133","doi-asserted-by":"publisher","first-page":"e0172957","DOI":"10.1371\/journal.pone.0172957","volume":"12","author":"A Schumacher","year":"2017","unstructured":"Schumacher A, Sikov WM, Quesenberry MI, Safran H, Khurshid H, Mitchell KM et al (2017) Informed consent in oncology clinical trials: a Brown University Oncology Research Group prospective cross-sectional pilot study. PLoS ONE 12(2):e0172957","journal-title":"PLoS ONE"},{"issue":"3","key":"3233_CR134","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1210\/er.2008-0031","volume":"30","author":"B Lo","year":"2009","unstructured":"Lo B, Parham L (2009) Ethical issues in stem cell research. Endocr Rev 30(3):204\u2013213","journal-title":"Endocr Rev"},{"key":"3233_CR135","unstructured":"Trials of war criminals before the Nuremberg Military Tribunals under Control Council Law No. 10"},{"issue":"10","key":"3233_CR136","doi-asserted-by":"publisher","first-page":"e047813","DOI":"10.1136\/bmjopen-2020-047813","volume":"11","author":"C Sawyer","year":"2021","unstructured":"Sawyer C, Preston L, Taylor S, Davies M, Carter L, Krebs M et al (2021) Oncology patients\u2019 experiences in experimental medicine cancer trials: a qualitative study. BMJ Open 11(10):e047813","journal-title":"BMJ Open"},{"issue":"8","key":"3233_CR137","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1590\/S1807-59322009000800016","volume":"64","author":"JY Chen","year":"2009","unstructured":"Chen JY, Scerbo M, Kramer G (2009) A review of blood substitutes: examining the history, clinical trial results, and ethics of hemoglobin-based oxygen carriers. Clinics (Sao Paulo) 64(8):803\u2013813","journal-title":"Clinics (Sao Paulo)"},{"issue":"1","key":"3233_CR138","doi-asserted-by":"publisher","first-page":"33","DOI":"10.4103\/0974-2077.41159","volume":"1","author":"KH Satyanarayana Rao","year":"2008","unstructured":"Satyanarayana Rao KH (2008) Informed consent: an ethical obligation or legal compulsion? J Cutan Aesthet Surg 1(1):33\u201335","journal-title":"J Cutan Aesthet Surg"},{"issue":"3","key":"3233_CR139","doi-asserted-by":"publisher","first-page":"107","DOI":"10.4103\/picr.PICR_147_16","volume":"8","author":"RA Kadam","year":"2017","unstructured":"Kadam RA (2017) Informed consent process: a step further towards making it meaningful! Perspect Clin Res 8(3):107\u2013112","journal-title":"Perspect Clin Res"},{"key":"3233_CR140","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jcrc.2018.04.008","volume":"51","author":"F Marrazzo","year":"2019","unstructured":"Marrazzo F, Larson G, Sherpa Lama TT, Teggia Droghi M, Joyce M, Ichinose F et al (2019) Inhaled nitric oxide prevents systemic and pulmonary vasoconstriction due to hemoglobin-based oxygen carrier infusion: a case report. J Crit Care 51:213\u2013216","journal-title":"J Crit Care"},{"issue":"1","key":"3233_CR141","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1186\/s12951-024-02606-1","volume":"22","author":"K Zhu","year":"2024","unstructured":"Zhu K, Wang L, Xiao Y, Zhang X, You G, Chen Y et al (2024) Nanomaterial-related hemoglobin-based oxygen carriers, with emphasis on liposome and nano-capsules, for biomedical applications: current status and future perspectives. J Nanobiotechnol 22(1):336","journal-title":"Journal of nanobiotechnology"},{"key":"3233_CR142","doi-asserted-by":"crossref","unstructured":"Alayash AI (2019) Mechanisms of toxicity and modulation of hemoglobin-based oxygen carriers. Shock 52(1S Suppl 1):41\u201349","DOI":"10.1097\/SHK.0000000000001044"},{"issue":"3","key":"3233_CR143","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1006\/bbrc.2000.3025","volume":"273","author":"E Nagababu","year":"2000","unstructured":"Nagababu E, Rifkind JM (2000) Heme degradation during autoxidation of oxyhemoglobin. Biochem Biophys Res Commun 273(3):839\u2013845","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"3233_CR144","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1161\/CIRCRESAHA.119.315626","volume":"126","author":"RT Premont","year":"2020","unstructured":"Premont RT, Reynolds JD, Zhang R, Stamler JS (2020) Role of nitric oxide carried by hemoglobin in cardiovascular physiology: developments on a three-gas respiratory cycle. Circ Res 126(1):129\u2013158","journal-title":"Circ Res"},{"key":"3233_CR145","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1097\/SHK.0000000000001009","volume":"52","author":"Gupta A Sen","year":"2019","unstructured":"Sen Gupta A (2019) Hemoglobin-based oxygen carriers: current state-of-the-art and novel molecules. Shock. 52:70\u201383","journal-title":"Shock."},{"issue":"1","key":"3233_CR146","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/jfb8010011","volume":"8","author":"K Taguchi","year":"2017","unstructured":"Taguchi K, Yamasaki K, Maruyama T, Otagiri M (2017) Comparison of the pharmacokinetic properties of hemoglobin-based oxygen carriers. J Funct Biomater 8(1):11","journal-title":"J Funct Biomater"},{"issue":"6","key":"3233_CR147","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S0049-3848(96)00213-7","volume":"84","author":"RW Stephens","year":"1996","unstructured":"Stephens RW, Orning L, Stormorken H, Hamers MJ, Petersen LB, Sakariassen KS (1996) Characterisation of cell-surface procoagulant activities using a microcarrier model. Thromb Res 84(6):453\u2013461","journal-title":"Thromb Res"},{"key":"3233_CR148","first-page":"803237","volume":"2014","author":"D Saha","year":"2014","unstructured":"Saha D, Patgaonkar M, Shroff A, Ayyar K, Bashir T, Reddy KV (2014) Hemoglobin expression in nonerythroid cells: novel or ubiquitous? Int J Inflamm 2014:803237","journal-title":"Int J Inflamm"},{"key":"3233_CR149","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.3389\/fonc.2019.01540","volume":"9","author":"V Fiorito","year":"2019","unstructured":"Fiorito V, Chiabrando D, Petrillo S, Bertino F, Tolosano E (2019) The multifaceted role of heme in cancer. Front Oncol 9:1540","journal-title":"Front Oncol"},{"issue":"8","key":"3233_CR150","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s00109-023-02350-3","volume":"101","author":"W Kruczkowska","year":"2023","unstructured":"Kruczkowska W, Kciuk M, Pasieka Z, Klosinski K, Pluciennik E, Elmer J et al (2023) The artificial oxygen carrier erythrocruorin-characteristics and potential significance in medicine. J Mol Med 101(8):961\u2013972","journal-title":"J Mol Med"},{"issue":"2","key":"3233_CR151","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ccc.2008.12.011","volume":"25","author":"J Creteur","year":"2009","unstructured":"Creteur J, Vincent JL (2009) Potential uses of hemoglobin-based oxygen carriers in critical care medicine. Crit Care Clin 25(2):311\u201324","journal-title":"Crit Care Clin"},{"issue":"3","key":"3233_CR152","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/mco2.55","volume":"2","author":"YP Liu","year":"2021","unstructured":"Liu YP, Zheng CC, Huang YN, He ML, Xu WW, Li B (2021) Molecular mechanisms of chemo- and radiotherapy resistance and the potential implications for cancer treatment. MedComm 2(3):315\u2013340","journal-title":"MedComm"}],"container-title":["Medical &amp; Biological Engineering &amp; Computing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11517-024-03233-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11517-024-03233-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11517-024-03233-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T19:50:38Z","timestamp":1743450638000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11517-024-03233-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,30]]},"references-count":152,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["3233"],"URL":"https:\/\/doi.org\/10.1007\/s11517-024-03233-6","relation":{},"ISSN":["0140-0118","1741-0444"],"issn-type":[{"type":"print","value":"0140-0118"},{"type":"electronic","value":"1741-0444"}],"subject":[],"published":{"date-parts":[[2024,11,30]]},"assertion":[{"value":"13 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study involves review of literature and analysis and does not involve directly or indirectly any patient sample, cell line, or even patients or normal subjects for participation in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The study does not involve any human subjects, so ethical approval and consent to participate is not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All the authors agree to the content of the manuscript and have no conflict of interest for authorship.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MKK has received consultant honoraria from the CBRS, Noida. The rest of the authors declare that they have no financial interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}